-
1.发明公开AMINO- IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA. 审中-公开氨基咪唑啉酮及其用作治疗认知障碍，阿尔茨海默病，神经退化和痴呆的药物。
公开(公告)号：EP2035425A1
公开(公告)日：2009-03-18
申请号：EP07748236.2
申请日：2007-06-12
发明人： BERG, Stefan , HOLENZ, Jörg , HÖGDIN, Katharina , KOLMODIN, Karin , PLOBECK, Niklas , ROTTICCI, Didier , SEHGELMEBLE, Fernando
IPC分类号： C07D487/04 , A61K31/519 , A61P25/28
CPC分类号： C07D487/04
摘要： This invention relates to novel compounds having the structural formula I below and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
摘要翻译： 本发明涉及具有下述结构式I的新化合物及其药学上可接受的盐，组合物和使用方法。 这些新型化合物提供了认知障碍，阿尔茨海默病，神经变性和痴呆的治疗或预防。
-
2.发明公开AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA 审中-公开氨基咪唑啉酮及其作为药物治疗认知障碍，阿尔茨海默病，神经退化和痴呆的药物
公开(公告)号：EP2044072A1
公开(公告)日：2009-04-08
申请号：EP07748237.0
申请日：2007-06-12
发明人： BERG, Stefan , HOLENZ, Jörg , HÖGDIN, Katharina , KOLMODIN, Karin , PLOBECK, Niklas , ROTTICCI, Didier , SEHGELMEBLE, Fernando , EK, Maria
IPC分类号： C07D487/04 , A61K31/519 , A61P25/28
CPC分类号： C07D487/04
摘要： This invention relates to novel compounds having the structural formula (I) below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
摘要翻译： 本发明涉及具有以下结构式（I）的新化合物：及其药学上可接受的盐，组合物和使用方法。 这些新型化合物提供了认知障碍，阿尔茨海默病，神经变性和痴呆的治疗或预防。
-
3.发明公开AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA. 审中-公开AMINOIMIDAZOLONE和它们作为治疗认知障碍阿尔茨海默氏症，老年痴呆症和神经变性治疗
公开(公告)号：EP2035424A1
公开(公告)日：2009-03-18
申请号：EP07748235.4
申请日：2007-06-12
发明人： BERG, Stefan , HOLENZ, Jörg , HÖGDIN, Katharina , KIHLSTRÖM, Jacob , KOLMODIN, Karin , LINDSTRÖM, Johan , PLOBECK, Niklas , ROTTICCI, Didier , SEHGELMEBLE, Fernando , EK, Maria
IPC分类号： C07D487/04 , A61K31/519 , A61P25/28
CPC分类号： C07D487/04
摘要： This invention relates to novel compounds having the structural formula (I) and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
-
4.发明公开AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA 审中-公开氨基咪唑啉酮及其作为药物治疗认知障碍，阿尔茨海默病，神经退化和痴呆的药物
公开(公告)号：EP2035423A1
公开(公告)日：2009-03-18
申请号：EP07748234.7
申请日：2007-06-12
发明人： BERG, Stefan , HÖGDIN, Katharina , KIHLSTRÖM, Jacob , PLOBECK, Niklas , SEHGELMEBLE, Fernando , EK, Maria
IPC分类号： C07D487/04 , A61K31/519 , A61P25/28
CPC分类号： C07D487/04
摘要： This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
摘要翻译： 本发明涉及具有下述结构式I的新化合物：及其药学上可接受的盐，组合物和使用方法。 这些新型化合物提供了认知障碍，阿尔茨海默病，神经变性和痴呆的治疗或预防。
-
公开(公告)号：EP3176172B1
公开(公告)日：2020-01-29
申请号：EP17150757.7
申请日：2011-12-21
申请人： Astrazeneca AB
发明人： CSJERNYIK, Gabor , KARLSTRÖM, Sofia , KERS, Annika , KOLMODIN, Karin , NYLÖF, Martin , ÖHBERG, Liselotte , RAKOS, Laszlo , SANDBERG, Lars , SEHGELMEBLE, Fernando , SÖDERMAN, Peter , SWAHN, Britt-Marie , VON BERG, Stefan
IPC分类号： C07D491/107 , A61K31/4184 , A61K31/4188 , A61K31/4439 , A61K31/506 , A61P25/28 , C07D401/04 , C07D235/02 , C07D401/12 , C07D403/12 , C07D405/12 , C07D491/20
-
公开(公告)号：EP3176172A1
公开(公告)日：2017-06-07
申请号：EP17150757.7
申请日：2011-12-21
申请人： Astrazeneca AB
发明人： CSJERNYIK, Gabor , KARLSTR M, Sofia , KERS, Annika , KOLMODIN, Karin , NYLÖF, Martin , ÖHBERG, Liselotte , RAKOS, Laszlo , SANDBERG, Lars , SEHGELMEBLE, Fernando , SÖDERMAN, Peter , SWAHN, Britt-Marie , VON BERG, Stefan
IPC分类号： C07D491/107 , A61K31/4184 , A61K31/4188 , A61K31/4439 , A61K31/506 , A61P25/28 , C07D401/04 , C07D235/02 , C07D401/12 , C07D403/12 , C07D405/12 , C07D491/20
摘要： The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aß-related pathologies such as Down's syndrome, ß- amyloid angiopathy such as, but not limited to, cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease.
摘要翻译： 本发明涉及式（I）的化合物及其药物组合物。 此外，本发明涉及用于治疗和/或预防Aβ相关病症如唐氏综合症，β-淀粉样血管病例如但不限于脑淀粉样血管病或遗传性脑出血的疾病的治疗方法，与 认知障碍，诸如但不限于MCI（“轻度认知障碍”），阿尔茨海默病，记忆丧失，与阿尔茨海默病相关的注意力缺陷症状，与诸如阿尔茨海默病的疾病相关的神经变性或包括混合血管和退行性起源的痴呆在内的痴呆， 老年痴呆症，老年痴呆症和帕金森病相关的痴呆症。
-
公开(公告)号：EP2655378A1
公开(公告)日：2013-10-30
申请号：EP11850232.7
申请日：2011-12-21
申请人： AstraZeneca AB
发明人： CSJERNYIK, Gabor , KARLSTRÖM, Sofia , KERS, Annika , KOLMODIN, Karin , NYLÖF, Martin , ÖHBERG, Liselotte , RAKOS, Laszlo , SANDBERG, Lars , SEHGELMEBLE, Fernando , SÖDERMAN, Peter , SWAHN, Britt-Marie , VON BERG, Stefan
IPC分类号： C07D491/107 , A61K31/4184 , A61K31/4188 , A61K31/4439 , A61K31/506 , A61P25/28 , C07D401/04 , C07D235/02 , C07D401/12 , C07D403/12 , C07D405/12 , C07D491/20
CPC分类号： A61K31/497 , A61K31/4184 , A61K31/4188 , A61K31/437 , A61K31/4439 , A61K31/506 , A61K45/06 , A61K2300/00 , C07D235/02 , C07D401/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D471/04 , C07D491/107 , C07D491/20
摘要： The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Αβ-related pathologies such as Down's syndrome, β- amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease.
-
公开(公告)号：EP2655378B1
公开(公告)日：2017-03-01
申请号：EP11850232.7
申请日：2011-12-21
申请人： AstraZeneca AB
发明人： CSJERNYIK, Gabor , KARLSTRÖM, Sofia , KERS, Annika , KOLMODIN, Karin , NYLÖF, Martin , ÖHBERG, Liselotte , RAKOS, Laszlo , SANDBERG, Lars , SEHGELMEBLE, Fernando , SÖDERMAN, Peter , SWAHN, Britt-Marie , VON BERG, Stefan
IPC分类号： C07D491/107 , A61K31/4184 , A61K31/4188 , A61K31/4439 , A61K31/506 , A61P25/28 , C07D401/04 , C07D235/02 , C07D401/12 , C07D403/12 , C07D405/12 , C07D491/20
CPC分类号： A61K31/497 , A61K31/4184 , A61K31/4188 , A61K31/437 , A61K31/4439 , A61K31/506 , A61K45/06 , A61K2300/00 , C07D235/02 , C07D401/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D471/04 , C07D491/107 , C07D491/20
-
9.发明公开NEW COMPOUNDS, PROCESS FOR THEIR PREPARATION, INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OF 5-HT6 MEDIATED DISORDERS SUCH AS ALZHEIMER'S DISEASE, COGNITIVE DISORDERS, COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA, OBESITY AND PARKINSON'S DISEASE 审中-公开新化合物，其制备方法，中间体，药物组合物及其在治疗5-HT6介导的疾病中的用途，例如阿尔茨海默病，认知障碍，与精神分裂症，肥胖和帕金森病有关的认知性损害
公开(公告)号：EP1910321A1
公开(公告)日：2008-04-16
申请号：EP06758020.9
申请日：2006-07-03
申请人： AstraZeneca AB
IPC分类号： C07D267/14 , A61K31/55 , A61K31/553 , A61P25/16 , A61P25/28 , A61P3/04 , C07D223/16 , C07D401/12 , C07D401/14 , C07D407/12 , C07D409/12 , C07D417/12 , C07D513/04
CPC分类号： C07D267/14 , C07D223/16 , C07D267/12 , C07D401/12 , C07D401/14 , C07D413/12 , C07D417/12 , C07D498/04 , C07D513/04 , C07D513/14
摘要： The present invention relates to new compounds of formula (I), or salts, solvates or solvated salts thereof, process for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in the treatment of 5-HT6 mediated disorders such as Alzheimer's disease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and Parkinson's disease.
摘要翻译： 本发明涉及式（I）的新化合物或其盐，溶剂合物或溶剂化盐，其制备方法和用于其制备的新中间体，含有所述化合物的药物组合物以及所述化合物在 治疗5-HT6介导的疾病如阿尔茨海默病，认知障碍，与精神分裂症有关的认知障碍，肥胖症和帕金森病。
-
10.发明公开NEW COMPOUNDS, PROCESS FOR THEIR PREPARATION, INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OF 5-HT6 MEDIATED DISORDERS SUCH AS ALZHEIMER S DESEASE, COGNITIVE DISORDERS, COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA, OBESITY AND PARKINSON'S DISEASE 审中-公开新化合物，制造，中间体，药物组合物及其使用在治疗5-HT6介导的疾病，如阿尔茨海默氏症，精神分裂症相关的认知障碍认知障碍，肥胖和帕金森氏方法
公开(公告)号：EP1902041A1
公开(公告)日：2008-03-26
申请号：EP06747985.7
申请日：2006-07-03
申请人： AstraZeneca AB
IPC分类号： C07D267/14 , A61K31/553 , A61P25/16 , A61P25/28 , A61P3/04
CPC分类号： C07D223/16 , C07D243/14 , C07D267/14
摘要： The present invention relates to new compounds of formula I, or salts, solvates or solvated salts thereof, process for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in the treatment of 5-HT6 mediated disorders such as Alzheimer's disease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and Parkinson's disease.
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.029 秒)
